We collaborated with artist Stephanie Fonteyn to celebrate the molecules that have become lifesaving medicines and are helping to accelerate efforts to end malaria for good.
As the world continues to fight the COVID-19 pandemic, more than ever, we are reminded of the crucial need to invest in research and development for affordable medicines.
Medicines for Malaria Venture was created at a time when the antimalarial pipeline was virtually empty, and malaria was killing over 1 million people every year. Ever since this time, MMV's scientists, physicians and partners have worked tirelessly to build the largest portfolio of medicines for malaria in history.
The first high-quality, fixed-dose, artemisinin-based combination therapy tailored to children's needs (co-developed with Novartis). To date, it is estimated to have saved over 840,000 lives.
Co-developed with Alfasigma, and stringently approved as a treatment for uncomplicated malaria in 2011, today, it is being investigated as a preventive treatment for populations at greater risk of severe infection, like pregnant women.
Sulfadoxine-pyrimethamine + amodiaquine (SPAQ)
Every rainy season, SPAQ is deployed as seasonal malaria chemoprevention, protecting over 200 million children in the sub-Sahel region of Africa.
The first-ever single dose treatment to prevent relapse of Plasmodium vivax malaria (co-developed with GSK).
* Trademarks owned by GSK
Artesunate injections and artesunate rectocaps
Injectable artesunate has saved an estimated 1 million lives more than quinine would have since 2011, while artesunate rectocaps, a pre-referral intervention, saved 400,000 lives since 2017.
The only artemisinin-based combination therapy approved by a stringent regulatory authority to treat both Plasmodium falciparum and Plasmodium vivax malaria (co-developed with Shin Poong).